title: Canine Osteosarcoma Treated by Post-Amputation Sequential Accelerated Doxorubicin and Carboplatin Chemotherapy: 38 Cases.
abstract: Canine appendicular osteosarcoma is an important clinical problem in veterinary medicine. Current standard therapy includes amputation followed by chemotherapy, which improves outcomes; however the percentage of long-term survival is still relatively low at 15-20%. Established prognostic factors include serum alkaline phosphatase level, histologic grade, and lymphocyte and monocyte counts. We used a protocol with shorter inter-treatment intervals than standard, but which we expected to still be well-tolerated, based on drugs known to be active agents, with the aim of improving outcomes by increasing dose intensity. Thirty-eight dogs with confirmed appendicular osteosarcoma and no pulmonary metastases that underwent amputation followed by this chemotherapy protocol were retrospectively evaluated. The median survival time was 317 days and 1- and 2-yr survival percentages were 43.2% and 13.9%, respectively. Toxicity was comparable to that seen with other standard dose protocols, with 5.2% of dogs hospitalized for complications that resolved with supportive care and no chemotherapy-related mortality. Serum alkaline phosphatase level (normal or high) (p = 0.004) and whether or not chemotherapy was completed (p = 0.001) were found to significantly impact survival time on multivariate analysis. Outcomes were similar to those reported with most other published chemotherapy protocols for dogs with this disease.
authors.affiliation: From Veterinary Oncology Consultants, Wauchope, Australia (A.E.F., A.S.M.); and Animal Referral Hospital, Sydney, Australia (C.M.C.).
authors.forename: Angela E
authors.initials: AE
authors.lastname: Frimberger
authors.affiliation: From Veterinary Oncology Consultants, Wauchope, Australia (A.E.F., A.S.M.); and Animal Referral Hospital, Sydney, Australia (C.M.C.).
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Chan
authors.affiliation: From Veterinary Oncology Consultants, Wauchope, Australia (A.E.F., A.S.M.); and Animal Referral Hospital, Sydney, Australia (C.M.C.).
authors.forename: Antony S
authors.initials: AS
authors.lastname: Moore
mesh_terms: D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D001859:Bone Neoplasms / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D016190:Carboplatin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000601:surgery / Q000628:therapy*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D016190:Carboplatin